Response to Commentary "Are Parenchyma-Sparing Resections Really Appropriate for Small (<3 cm) Non-Functional Pancreatic Neuroendocrine Tumors?"

Affiliations

¹ From the Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
² Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
⁴ Department of Surgery, Johns Hopkins Hospital, Baltimore, MD.

Louisa Bolm et al. Ann Surg Open. 2023.

. 2023 Feb 20;4(1):e245.

doi: 10.1097/AS9.0000000000000245. eCollection 2023 Mar.

¹ From the Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
² Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
⁴ Department of Surgery, Johns Hopkins Hospital, Baltimore, MD.

No abstract available

References

1. Bolm L, Nebbia M, Wei AC, et al. . Long-term outcomes of parenchyma-sparing and oncologic resections in patients with nonfunctional pancreatic neuroendocrine tumors <3 cm in a large multicenter cohort. Ann Surg. 2022;276:522–531. - PMC - PubMed
1. Halfdanarson TR, Strosberg JR, Tang L, et al. . The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49:863–881. - PubMed
1. Dong D-H, Zhang X-F, Poultsides G, et al. . Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: a multi-institutional study of 392 cases. J Surg Oncol. 2019;120:1071–1079. - PMC - PubMed
1. Genç CG, Jilesen AP, Partelli S, et al. . A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann Surg. 2018;267:1148–1154. - PubMed
1. Lindner K, Binte D, Hoeppner J, et al. . Resection of non-functional pancreatic neuroendocrine neoplasms-a single-center retrospective outcome analysis. Curr Oncol Tor Ont. 2021;28:3071–3080. - PMC - PubMed